| DC20847 |
CL 316243 |
CL 316243 (BTA 243) is a potent, highly selective, orally active β3-adrenoceptor agonist with EC50 of 3 nM. |
|
| DC20909 |
CL 316243 disodium |
CL 316243 is a potent, highly selective, orally active β3-adrenoceptor agonist with EC50 of 3 nM. |
|
| DC20910 |
CL-82198 hydrochloride |
CL-82198 is a potent, selective inhibitor of MMP-13 (89% inhibition at 10 ug/mL), displays no activity at MMP-1, MMP-9 and TACE, significantly reduces the migration of LS174 cells by 55% at 10 uM.. |
|
| DC4205 |
Cladribine |
Cladribine (Leustatin, Litak, 2CDA) is an adenosine deaminase inhibitor for U266, RPMI8226, and MM1.S cells with IC50 of approximately 2.43 μM, 0.75 μM, and 0.18 μM, respectively. |
|
| DC12292 |
Cl-amidine hydrochloride
Featured
|
Cl-amidine (hydrochloride) is a peptidylarginine deminase (PAD) inhibitor, with an IC50 5.9 μM for PAD4. |
|
| DC9868 |
Clanfenur
Featured
|
Clanfenur is a substituted benzoylphenylurea and an analogue of the pesticide diflubenzuron with potential antineoplastic activity. |
|
| DC8937 |
Clarithromycin |
Clarithromycin is a macrolide antibiotic and a CYP3A4 inhibitor. |
|
| DC12407 |
Class I and IIB HDAC inhibitor 42 |
Class I and IIB HDAC inhibitor 42 is a novel potent, selective class I and IIB inhibitor (HDAC1 Ki=0.27 nM) for topical treatment of cutaneous t-cell lymphoma.. |
|
| DC10204 |
Clinofibrate |
Clinofibrate (S-8527) is a hypelipidemic agent and a HMG-CoA reductase inhibitor. |
|
| DC10242 |
5-Chloro-8-hydroxy-7-iodoquinoline |
Clioquinol is an orally bioavailable, lipophilic, copper-binding, halogenated 8-hydroxyquinoline with antifungal, antiparasitic and potential antitumor activities. |
|
| DC21722 |
CLK-IN-T3
Featured
|
CLK inhibitor T3 (T3) is a highly potent, selective, and cell-based stable CDC-like kinase (CLK) inhibitor with 0.67, 15 and 110 nM for CLK1,2 and 3, respectively. |
|
| DC11004 |
CLK2 inhibitor Indazole1 |
CLK2 inhibitor Indazole1 is a novel potent, selective inhibitor of CLK2 with IC50 of 2.7 nM, 60-fold selectivity over PKA and >600-fold selectivity over a panel of 34 kinases. |
|
| DC23464 |
Clobenpropit |
Clobenpropit (VUF-9153) is a highly potent histamine H3 antagonist/inverse agonist with pA2 value of 9.93, also displays partial agonist activity at H4 receptors. |
|
| DC23440 |
Clobenpropit dihydrobromide |
Clobenpropit (VUF-9153) is a highly potent histamine H3 antagonist/inverse agonist with pA2 value of 9.93, also displays partial agonist activity at H4 receptors. |
|
| DC12304 |
Clocapramine hydrochloride hydrate (3-Chlorocarpipramine hydrochloride hydrate) |
Clocapramine hydrochloride hydrate is an antagonist of the D2 and 5-HT2A receptors. |
|
| DC8681 |
Clofentezine |
Clofentezine, a growth inhibitor, has sublethal effects on life-table parameters of Tetranychus urticae Koch females. |
|
| DC3147 |
Clopidogrel hydrogensulfate |
Clopidogrel (Plavix) is an oral, thienopyridine class antiplatelet agent. |
|
| DC8672 |
Cloquintocet-mexyl |
Cloquintocet-mexyl is a herbicide, used to control coarse annual grass of the family poaceae (gramineae). |
|
| DC7991 |
8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e](1,4)diazepine N-oxide
Featured
|
Clozapine N-oxide is a major metabolite of Clozapine noted to decrease SR-2A (5-HT2 serotonin receptor) density in vitro. |
|
| DC12714 |
CLP-290
Featured
|
CLP290 (CLP-290) is an orally acirtve small molecule K+-Cl- cotransporter isotype 2 (KCC2) activator, the carbamate prodrug of CLP257; In vivo co-treatment with morphine and oral CLP290 prevented membrane KCC2 downregulation in SDH neurons. Concurrently, co-treatment with CLP290 significantly mitigated MIH and acute administration of CLP257 in established MIH restored normal nociceptive behavior. |
|
| DC11061 |
ClpP inhibitor M21 |
ClpP inhibitor M21 is a noncompetitive inhibitor of ClpP with IC50 of 41.42 uM, inhibits ClpP cleavage of SUc-LY-AMC substrate in a peptidase assay. |
|
| DC11067 |
CLSP37 |
CLSP37 (RIPK2 inhibitor CLSP37) is a novel potent, ATP pocket-binding RIPK2 inhibitor with IC50 of 16.3 nM in ADPGlo assay, demonstrates inhibition of both the RIPK2-XIAP interaction, and of cellular and in vivo NOD2 signaling. |
|
| DC11068 |
CLSP43 |
CLSP43 (RIPK2 inhibitor CLSP43) is a novel potent, ATP pocket-binding RIPK2 inhibitor with IC50 of 19.9 nM in ADPGlo assay, demonstrates inhibition of both the RIPK2-XIAP interaction, and of cellular and in vivo NOD2 signaling. |
|
| DC21063 |
CM03 |
CM03 is a G-quadruplex-binding compound that potently inhibits cell growth in PDAC cell lines (MIA PaCa-2 IC50=19 nM). |
|
| DC12629 |
CM-675 |
CM-675 (CM675) is a potent, dual PDE5 and classI-HDAC inhibitor with IC50 of 114/673 nM for PDE5A/HDAC1, respectively. |
|
| DC20913 |
CMA-008 |
CMA-008 is a cell-permeable, small molecule modulator of NAADP-mediated Ca2+ release, competes with NAADP binding, inhibit Ca2+ release via the NAADP receptor (IC50=15 uM-1 mM). |
|
| DC23813 |
CMC2.24 |
CMC2.24 (TRB-N0224) is a novel tricarbonylmethane agent that inhibits the Ras-RAF-MEK-ERK pathway, inhibits Ras activation in pancreatic cancer both in vitro and in vivo. |
|
| DC7388 |
c-Met inhibitor 1 |
c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer. |
|
| DC9617 |
CMK |
CMK is a RSK2 kinase inhibitor. |
|
| DC21530 |
CMP-5
Featured
|
CMP-5 (PRMT5-IN-5) is a first-in-class, small-molecule inhibitor that specifically targets protein arginine methyltransferase 5 (PRMT5), an enzyme involved in epigenetic regulation and cellular signaling. PRMT5 catalyzes the symmetric dimethylation of arginine residues on histones and other proteins, playing a critical role in gene expression, cell proliferation, and survival. CMP-5 has shown remarkable specificity in blocking Epstein-Barr virus (EBV)-driven B-lymphocyte transformation and survival, while sparing normal B cells, making it a promising therapeutic candidate for EBV-associated cancers and other PRMT5-dependent diseases. |
|
